^
    1d
    PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD-1 blockade. (PubMed, Clin Transl Med)
    Our findings indicate that aberrant PI3K/mTOR pathway activation contributes to immune escape in uLMS and provides a rationale for combining PI3K/mTOR inhibition with ICB for the treatment of this patient population.
    Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    10d
    Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis. (PubMed, Anticancer Res)
    Pretreatment SIRI can be considered a biomarker for the prognostic prediction of patients with STS treated with trabectedin.
    Retrospective data • Journal
    |
    CRP (C-reactive protein)
    |
    Yondelis (trabectedin)
    13d
    Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Phase classification: P1b --> P1 | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Bavencio (avelumab) • vimseltinib (DCC-3014)
    14d
    Novel MIR143HG::PLAG1 gene fusion identified in a rectal myxoid leiomyosarcoma. (PubMed, Genes Chromosomes Cancer)
    Recently five cases of MLS were reported to harbor PLAG1 fusions (TRPS1::PLAG1, RAD51B::PLAG1, and TRIM13::PLAG1). In this report, we present a case of rectal MLS with a novel MIR143HG::PLAG1 fusion detected by RNA next-generation sequencing.
    Journal
    |
    RAD51B (RAD51 Paralog B) • MIR143 (MicroRNA 143) • PLAG1 (PLAG1 Zinc Finger) • TRPS1 (Transcriptional Repressor GATA Binding 1)
    15d
    FOXO3a deregulation in uterine smooth muscle tumors. (PubMed, Clinics (Sao Paulo))
    In summary, the outcomes of the present study suggest that the imbalance in FOXO3a within Uterine Smooth Muscle Tumors might arise from both protein phosphorylation and miRNA activity. FOXO3a could emerge as a promising therapeutic target for individuals with Unusual Leiomyomas and Leiomyosarcomas (ULM and LMS), offering novel directions for treatment strategies.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • MIR155 (MicroRNA 155) • FOXO3 (Forkhead box O3) • MIR96 (MicroRNA 96) • Let-7c (MicroRNA Let-7c)
    |
    HER-2 expression • VEGFA expression
    18d
    Benign metastasizing fumarate hydratase (FH)-deficient uterine leiomyomas: clinicopathological and molecular study with first documentation of multi-organ metastases. (PubMed, Virchows Arch)
    These novel cases highlight a rare but possibly under-recognized presentation of FH-d BML. Our study suggests that FH-d BML cases might be enriched for the HLRCC syndrome.
    Journal • Metastases
    |
    FH (Fumarate Hydratase)
    21d
    LP-184, a novel acylfulvene molecule, exhibits anti-cancer activity against diverse solid tumors with homologous recombination deficiency. (PubMed, Cancer Res Commun)
    These preclinical findings illustrate the potential of LP-184 as a pan-HRD cancer therapeutic. Taken together, our results support continued clinical evaluation of LP-184 in a large subset of HRD solid tumors.
    Journal • BRCA Biomarker • PARP Biomarker
    |
    BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • PTGR1 (Prostaglandin Reductase 1)
    |
    HRD
    |
    hydroxyureamethylacylfulvene (STAR-001)
    21d
    New treatment strategies for uterine sarcoma using secreted frizzled‑related proteins. (PubMed, Exp Ther Med)
    In conclusion, SFRP4 may suppress the viability and migration, and enhance the adhesion of sarcoma cells. These results suggested that SFRP4 could be considered as a novel therapeutic target for uterine sarcoma.
    Journal
    |
    SFRP4 (Secreted frizzled-related protein 4)
    |
    KIT expression
    22d
    Lurbinectedin + Doxorubicin In Leiomyosarcoma (clinicaltrials.gov)
    P1/2, N=62, Recruiting, Massachusetts General Hospital | Phase classification: P1b/2 --> P1/2
    Phase classification
    |
    doxorubicin hydrochloride • Zepzelca (lurbinectedin)
    28d
    Uterine myxoid leiomyosarcoma: identification of a novel PLAG1 fusion partner. (PubMed, Pathology)
    No abstract available
    Journal
    |
    PLAG1 (PLAG1 Zinc Finger)
    1m
    A Study of Nivolumab in Selected Uterine Cancer Patients (clinicaltrials.gov)
    P2; Active, not recruiting --> Completed | Trial completion date: Aug 2024 --> Apr 2024 | Trial primary completion date: Aug 2024 --> Apr 2024
    Trial completion date • Trial primary completion date • Trial completion • Mismatch repair
    |
    MSI-H/dMMR
    |
    MSK-IMPACT
    |
    Opdivo (nivolumab)
    1m
    Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Combination therapy • Metastases
    |
    PD-1 (Programmed cell death 1)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • ABP 206 (nivolumab biosimilar)
    1m
    Roles of Matrix Metalloproteinases 2 and 9 in Uterine Leiomyosarcoma. (PubMed, Anticancer Res)
    Expression levels of MMP2 and MMP9 were upregulated in malignant uLMS tumors when compared with those in benign uterine leiomyoma tumors. Increased MMP2 expression might promote uLMS invasion and migration. MMP9 overexpression might be related to uLMS occurrence; however, it protects against uLMS invasion and metastasis. MMP2 and MMP9 may be potential predictors of uLMS cell proliferation, metastasis, and prognosis. These findings could be helpful in developing new strategies for diagnosing and treating uLMS.
    Journal
    |
    MMP2 (Matrix metallopeptidase 2) • MMP9 (Matrix metallopeptidase 9)
    |
    MMP9 overexpression
    2ms
    Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=66, Suspended, National Cancer Institute (NCI) | Recruiting --> Suspended
    Trial suspension • Tumor mutational burden • IO biomarker • Metastases
    |
    TMB (Tumor Mutational Burden) • CD68 (CD68 Molecule)
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Cabometyx (cabozantinib tablet) • ABP 206 (nivolumab biosimilar)
    2ms
    Expanding the Spectrum of NR4A3 Fusion-Positive Gynecologic Leiomyosarcomas. (PubMed, Mod Pathol)
    All cases showed high NR4A3 RNA expression levels and NOR1 (NR4A3) nuclear staining similar to salivary gland acinic cell carcinoma and a subset of extraskeletal myxoid chondrosarcomas harboring NR4A3 rearrangement. NOR1 (NR4A3) immunohistochemistry may serve as a useful diagnostic marker of NR4A3 fusion-positive gynecologic leiomyosarcomas.
    Journal
    |
    NR4A3 (Nuclear receptor subfamily 4 group A member 3) • MME (Membrane Metalloendopeptidase) • SLCO5A1 (Solute Carrier Organic Anion Transporter Family Member 5A1)
    2ms
    Uterine Leiomyosarcoma Associated With Perivascular Epithelioid Cell Tumor: A Phenomenon of Differentiation/Dedifferentiation and Evidence Suggesting Cell-of-Origin. (PubMed, Am J Surg Pathol)
    We hypothesize that LMSs containing smooth muscle progenitor cells may give rise to divergent, lineage-specific PEComatous lesions through differentiation or dedifferentiation. While we do not dispute the recognition of PEComas as a distinct entity, we advocate the hypothesis that modified smooth muscle cells represent the origin of a subset of PEComas, and our case series provides evidence to suggest this theory.
    Journal
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • ATRX (ATRX Chromatin Remodeler) • FH (Fumarate Hydratase) • GPNMB (Glycoprotein Nmb) • CTSK (Cathepsin K)
    |
    TP53 mutation • RB1 expression • TP53 expression • TP53 R196*
    2ms
    A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients (clinicaltrials.gov)
    P1, N=56, Active, not recruiting, University Health Network, Toronto | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Xpovio (selinexor)
    2ms
    Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma. (PubMed, Clin Cancer Res)
    Compared to traditional clinicopathologic models, genomic risk stratification demonstrates superior prediction of clinical outcome in STLMS and is comparable in ULMS.
    Journal
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • RB1 mutation • ATRX mutation
    2ms
    DAPPER: Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P2, N=90, Active, not recruiting, University Health Network, Toronto | Trial completion date: Dec 2023 --> Jan 2025 | Trial primary completion date: Dec 2023 --> Jan 2025
    Trial completion date • Trial primary completion date • IO biomarker • Pan tumor • Metastases
    |
    HRD (Homologous Recombination Deficiency) • CD4 (CD4 Molecule)
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • Recentin (cediranib)
    2ms
    A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS) (clinicaltrials.gov)
    P1, N=41, Completed, PTC Therapeutics | Active, not recruiting --> Completed
    Trial completion • Combination therapy • Metastases
    |
    dacarbazine • unesbulin (BMIi-1)
    2ms
    A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions (clinicaltrials.gov)
    P1, N=12, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial • Metastases
    |
    gemcitabine • Fyarro (nanoparticle albumin-bound rapamycin)
    2ms
    A Case of Resection of Leiomyosarcoma Suspected to Originate from the Right Ovarian Vein (PubMed, Gan To Kagaku Ryoho)
    Additional immunostaining showed positive for α-SMA, caldesmon, calponin, and negative for desmin, CD34, CKA1/AE3, S100. Based on the intraoperative findings, we diagnosed it as leiomyosarcoma arising of the right ovarian vein.
    Journal
    |
    CD34 (CD34 molecule)
    2ms
    Conjunctival leiomyosarcoma: A clinico-pathological study with in deep molecular characterization. (PubMed, Pathol Res Pract)
    An uncommon molecular finding observed in our case was the presence of TSC1 gene mutation usually associated with soft tissue and gynecological PEComas. Our finding may harbor important therapeutic implications since the inactivation of the tumor suppressor genes TSC1 and TSC2 lead to upregulation of mTOR signaling, providing the rationale for target therapy with mTOR inhibitors. Additional studies on larger series are needed to validate our findings.
    Clinical • Clinical guideline • Observational data • Retrospective data • Review • Clinical Trial,Phase I • Journal
    |
    TMB (Tumor Mutational Burden) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1) • SOX10 (SRY-Box 10) • VIM (Vimentin) • CD99 (CD99 Molecule)
    |
    TMB-H • TSC1 mutation
    2ms
    Detection of MDM2 gene amplification by fluorescence in situ hybridization and its diagnostic value in low-grade osteosarcoma (PubMed, Zhonghua Bing Li Xue Za Zhi)
    The interpretation criteria for FISH detection of MDM2 amplification are currently not unified. The signal characteristics need more attention when interpreting.
    Journal
    |
    MDM2 (E3 ubiquitin protein ligase)
    |
    MDM2 amplification
    2ms
    NM32-2668 in Adult Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, Numab Therapeutics AG
    New P1 trial • Trispecific • Metastases
    2ms
    The utility of clinical sequencing in the diagnosis and treatment of soft tissue sarcomas; Real world data based on nation-wide database (AACR 2024)
    From 2019 to 2022, 1387 patients with STS were registered in C-CAT. The histological types included leiomyosarcoma in 357 patients, dedifferentiated liposarcoma in 178 patients, and undifferentiated pleomorphic sarcoma in 82 patients, and the others. The most commonly altered genes included TP53, CDKN2A, Rb1, and CDKN2B.
    Real-world evidence • Clinical • Tumor mutational burden • MSi-H Biomarker • Real-world
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • BCOR (BCL6 Corepressor) • EWSR1 (EWS RNA Binding Protein 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • NTRK (Neurotrophic receptor tyrosine kinase) • DUX4 (Double Homeobox 4)
    |
    TMB-H • MSI-H/dMMR • NTRK fusion
    |
    FoundationOne® CDx
    2ms
    NCI-2019-08556: Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma (clinicaltrials.gov)
    P1, N=14, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jan 2025 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Jan 2025
    Trial completion date • Trial primary completion date • Surgery
    |
    Opdivo (nivolumab) • polyinosinic:polycytidylic acid (BO-112)
    2ms
    TTI-621-03: A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma (clinicaltrials.gov)
    P2, N=76, Terminated, Pfizer | Phase classification: P1/2 --> P2 | Active, not recruiting --> Terminated; Pfizer decided to terminate the study for administrative reasons. The termination was neither due to safety concerns nor a request from the regulatory authorities.
    Phase classification • Trial termination • Combination therapy • Metastases
    |
    doxorubicin hydrochloride • ontorpacept (PF-07901800)
    2ms
    Atypical spindle cell/pleomorphic lipomatous tumor with sarcomatous transformation: clinicopathologic and molecular analysis of four cases. (PubMed, Mod Pathol)
    Limited clinical follow-up showed no recurrence or metastasis after 1-13 months (median 4.5 months) post-surgical excision. Altogether, our data support that ASPLT can rarely develop sarcomatous transformation and offers insights into the molecular mechanisms underlying this event.
    Journal
    |
    TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • ATRX (ATRX Chromatin Remodeler)
    |
    RB1 deletion • RB1 expression
    2ms
    Uterine leiomyosarcoma cell-derived extracellular vesicles induce the formation of cancer-associated fibroblasts. (PubMed, Biochim Biophys Acta Mol Basis Dis)
    miR-654-3p and miR-369-3p are highly expressed in ULMS-derived EVs, indicating that these EV-related miRNAs induce the formation of cancer-associated fibroblasts.
    Journal
    |
    ACTA2 (Actin Alpha 2 Smooth Muscle)
    2ms
    MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma (clinicaltrials.gov)
    P2, N=148, Not yet recruiting, HRYZ Biotech Co.
    New P2 trial
    |
    doxorubicin hydrochloride • ifosfamide
    3ms
    Letrozole in Uterine Leiomyosarcoma (clinicaltrials.gov)
    P2, N=40, Recruiting, GOG Foundation | Not yet recruiting --> Recruiting
    Enrollment open
    |
    ER (Estrogen receptor)
    |
    letrozole
    3ms
    Molecular profile and actionability of sarcomas with next-generation sequencing: Insights from a single institution in Brazil (Sarcoma-RC 2024)
    Despite the limitation of sample size, our study identified actionable alterations in 28% of tumor samples submitted to CGP. A high level of evidence of clinical activity according to OncoKB criteria was noted in 41% of actionable alterations. These findings underscore the importance of comprehensive genomic profiling in managing sarcomas.
    Clinical • Tumor mutational burden • Next-generation sequencing
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • CCNE1 (Cyclin E1) • MSH6 (MutS homolog 6) • CDK4 (Cyclin-dependent kinase 4) • KDM6A (Lysine Demethylase 6A) • MDM4 (The mouse double minute 4) • MUTYH (MutY homolog) • PAX3 (Paired Box 3)
    |
    TMB-H
    |
    TruSight Oncology 500 Assay
    3ms
    Primary Sarcomas of the Bladder (Bsarc) and Prostate (Psarc): A Genomic Landscape Study (USCAP 2024)
    GA in TP53, ATRX and RB1 were the most common GA identified in Bsarc and Psarc. Bsarc have more than 2-fold more GA compared to Psarc. Further study of both Bsarc and Psarc designed to further subclassify and design novel treatment for these rare tumors appears warranted.
    Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • NF1 (Neurofibromin 1) • ATRX (ATRX Chromatin Remodeler) • TSC2 (TSC complex subunit 2) • BCOR (BCL6 Corepressor) • ERG (ETS Transcription Factor ERG) • TMPRSS2 (Transmembrane serine protease 2) • FLCN (Folliculin) • STAT6 (Signal transducer and activator of transcription 6) • NAB2 (NGFI-A Binding Protein 2)
    |
    PD-L1 expression • PTEN mutation • TMPRSS2-ERG fusion • FLCN mutation
    |
    PD-L1 IHC 22C3 pharmDx
    3ms
    CDK4/MDM2 Amplification Is a Rare Targetable Genomic Event in TP53/RB1-Wildtype Uterine Leiomyosarcoma (USCAP 2024)
    Overall, in our uLMS analysis, CDK4 and/or MDM2 amplification was identified in a small subset (2%) of uLMS, the majority of which are TP53/RB1-wildtype. This may suggest that CDK4/MDM2 amplification can be an alternative tumorigenic mechanism in this distinct class of uLMS, which may have therapeutic clinical implications, including possible use of specific cyclin-dependent kinase inhibitors.
    Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • MDM2 amplification • CDK4 amplification • MDM2 amplification + CDK4 amplification • RB1 wild-type • CDK4 mutation
    |
    FoundationOne® Heme CDx
    3ms
    Fumarate-Deficient Uterine Leiomyosarcoma: Molecular Confirmation of Four Cases (USCAP 2024)
    While exceedingly rarely, FH mutations may be found in uLMS. Confirmation of FH deficiency should not preclude the diagnosis of sarcoma in smooth muscle neoplasms that meet histologic criteria for malignancy.
    Clinical
    |
    TP53 (Tumor protein P53) • RB1 (RB Transcriptional Corepressor 1) • ATRX (ATRX Chromatin Remodeler) • FH (Fumarate Hydratase)
    |
    TP53 mutation • MET mutation • RB1 deletion • ATRX mutation • RB deletion
    |
    FoundationOne® Heme CDx
    3ms
    CDK4/MDM2 Amplification Is a Rare Targetable Genomic Event in TP53/RB1-Wildtype Uterine Leiomyosarcoma (USCAP 2024)
    Overall, in our uLMS analysis, CDK4 and/or MDM2 amplification was identified in a small subset (2%) of uLMS, the majority of which are TP53/RB1-wildtype. This may suggest that CDK4/MDM2 amplification can be an alternative tumorigenic mechanism in this distinct class of uLMS, which may have therapeutic clinical implications, including possible use of specific cyclin-dependent kinase inhibitors.
    Tumor mutational burden
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • MDM2 (E3 ubiquitin protein ligase) • CDK4 (Cyclin-dependent kinase 4) • ATRX (ATRX Chromatin Remodeler)
    |
    TP53 mutation • MDM2 amplification • CDK4 amplification • MDM2 amplification + CDK4 amplification • RB1 wild-type • CDK4 mutation
    |
    FoundationOne® Heme CDx
    3ms
    Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) (clinicaltrials.gov)
    P3, N=325, Active, not recruiting, Advenchen Laboratories, LLC | Trial completion date: Apr 2024 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Focus V (anlotinib) • dacarbazine
    3ms
    Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery (clinicaltrials.gov)
    P2/3, N=140, Active, not recruiting, National Cancer Institute (NCI)
    Trial completion date • Surgery
    |
    doxorubicin hydrochloride • Votrient (pazopanib) • cyclophosphamide • ifosfamide • daunorubicin
    3ms
    A Patient with Small Intestinal Leiomyosarcoma and Intussusception Who Underwent Single Port Surgery (PubMed, Gan To Kagaku Ryoho)
    With the establishment of an immunostaining-test-based classification, leiomyosarcoma is currently rare. In this study, we report a patient in whom single port surgery for intussusception related to small intestinal leiomyosarcoma was successful.
    Journal • Surgery
    |
    ANO1 (Anoctamin 1)
    3ms
    A multicentric case study of fibroblastic and myofibroblastic oral spindle cell lesions. (PubMed, J Oral Maxillofac Pathol)
    The diagnostic strategies need to be upgraded for the diagnosis of spindle cell lesions. Emphasis must be placed on cytomorphology, an immunohistochemistry (IHC) panel of markers is imperative for the accurate diagnosis of fibroblastic and myofibroblastic oral spindle cell lesions.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • CD34 (CD34 molecule) • VIM (Vimentin) • CD31 (Platelet and endothelial cell adhesion molecule 1) • STAT6 (Signal transducer and activator of transcription 6) • CD99 (CD99 Molecule) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    3ms
    Immune evasion in lung metastasis of leiomyosarcoma: upregulation of EPCAM inhibits CD8 T cell infiltration. (PubMed, Br J Cancer)
    EPCAM was upregulated in lung metastases of leiomyosarcoma, suggesting inhibition of CD8 T cell migration. Our findings suggest that EPCAM could serve as a potential novel therapeutic target for leiomyosarcoma.
    Journal • IO biomarker
    |
    CD8 (cluster of differentiation 8)